Search
Elraglusib
go.drugbank.com/drugs/DB16047InvestigationalElraglusib is under investigation in clinical trial NCT04218071 (Actuate 1901: 9-ING-41 in Myelofibrosis).
Amdizalisib
go.drugbank.com/drugs/DB21514InvestigationalAmdizalisib is under investigation in clinical trial NCT05713110 (A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory Lymphoma).
Fasudil
go.drugbank.com/drugs/DB08162InvestigationalFasudil has been investigated in Carotid Stenosis.
Felezonexor
go.drugbank.com/drugs/DB21067InvestigationalFelezonexor is under investigation in clinical trial NCT02667873 (A Trial of a Novel XPO1 Inhibitor in Participants With Advanced Solid Tumors). … The usage of the INN stem '-nexor' in the name indicates that Felezonexor is a nuclear export inhibitor.
Telenzepine
go.drugbank.com/drugs/DB19508InvestigationalTelenzepine is under investigation in clinical trial NCT01155531 (Safety & Tolerability of a Combination of Antidepressant and Peptic Ulcer Drug in Overweight Healthy Subjects). … The usage of the INN stem '-zepine' in the name indicates that Telenzepine is a tricyclic compound.
Setileuton
go.drugbank.com/drugs/DB19550InvestigationalSetileuton is under investigation in clinical trial NCT00404313 (The Effect of MK0633 in Patients With Chronic Asthma (0633-007)). Setileuton has a monoisotopic molecular weight of 463.12 Da. … The usage of the INN stem '-leuton' in the name indicates that Setileuton is a 5-lipo-oxygenase inhibitor, anti-inflammatory.
Icovamenib
go.drugbank.com/drugs/DB21669InvestigationalIcovamenib is under investigation in clinical trial NCT06152042 (Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus). Icovamenib has a monoisotopic molecular weight of 566.28 Da. … The usage of the INN stem '-menib' in the name indicates that Icovamenib is a menin interaction inhibitor.
Maropitant
go.drugbank.com/drugs/DB11427ExperimentalVet approvedIt was approved by the FDA in 2007 for use in dogs, and more recently has also been approved for use in cats. … Maropitant, used as maropitant citrate, is a neurokinin receptor antagonist, which was developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs.